文献速递临床试验与 GCP基础与转化研究

修饰mRNA流感疫苗的效力、免疫原性与安全性

Efficacy, Immunogenicity, and Safety of Modified mRNA Influenza Vaccine.
PubMed 文献 · N Engl J Med · 2025-01-01

这项3期试验将18至64岁健康成人随机分配接受四价修饰mRNA流感疫苗或已上市四价灭活流感疫苗,主要终点为实验室确诊流感样疾病的相对效力。mRNA组相对效力为34.5%(95%CI 7.4至53.9),达到非劣效和优效标准;对A/H3N2和A/H1N1抗体应答非劣效,但B株未达非劣效;mRNA组反应原性更常见。

要点

  • mRNA疫苗相对效力34.5%(95%CI 7.4至53.9),达到非劣效和优效。
  • 对A/H3N2和A/H1N1抗体应答非劣效,对B株未达非劣效。
  • mRNA组局部反应70.1% vs 对照组43.1%,全身事件65.8% vs 48.7%。

核心结论

  • 修饰mRNA疫苗相对对照疫苗对流感样疾病具有统计学优效,相对效力为34.5%(95%CI 7.4至53.9)。
  • mRNA疫苗对A/H3N2和A/H1N1株的免疫应答更强,但反应原性事件更多。

研究设计与样本

  • 3期随机对照试验,于2022-2023年流感季在美国、南非和菲律宾开展。
  • 纳入18至64岁健康成人,随机分配接受四价修饰mRNA流感疫苗(modRNA组)或已上市四价灭活流感疫苗(对照组)。
  • 共18476例参与者随机分组:modRNA组9225例,对照组9251例。
  • 主要终点为接种后至少14天实验室确诊流感样疾病的相对效力,并分析非劣效性和优效性。
  • 免疫原性采用血凝抑制(HAI)试验评估;接种后7天内评估反应原性,1个月内评估不良事件,6个月内评估严重不良事件。

主要发现

  • 相对效力为34.5%(95%CI 7.4至53.9),基于modRNA组57例和对照组87例流感样疾病病例,达到非劣效和优效标准。
  • 流感样疾病病例由A/H3N2和A/H1N1株引起,几乎无B株。
  • HAI试验抗体应答对甲型流感株显示非劣效,对乙型流感株未显示非劣效。
  • 两疫苗组均主要为轻或中度反应原性,但modRNA组报告更频繁:总体局部反应70.1% vs 43.1%,总体全身事件65.8% vs 48.7%。
  • 发热在modRNA组发生率为5.6%,对照组为1.7%;两组不良事件特征相似。

关键数值与推荐

  • 相对效力为非劣效和优效,相对效力34.5%(95%CI 7.4至53.9),基于modRNA组57例和对照组87例病例。
  • HAI抗体应答对甲型流感株非劣效,对乙型流感株未达非劣效。
  • 总体局部反应发生率modRNA组70.1% vs 对照组43.1%;总体全身事件65.8% vs 48.7%。
  • 发热发生率modRNA组5.6% vs 对照组1.7%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Influenza remains a major health burden despite the use of licensed vaccines. Nucleoside-modified messenger RNA (modRNA) influenza vaccines have shown promising immunogenicity against influenza and an acceptable safety profile in a phase 1-2 trial. METHODS: In this phase 3 trial, we randomly assigned healthy adults between the ages of 18 and 64 years to receive either a quadrivalent modRNA influenza vaccine (modRNA group) or a licensed inactivated quadrivalent influenza vaccine (control group) during the 2022-2023 influenza season in the United States, South Africa, and the Philippines. The primary end point was relative efficacy, defined by the reduction in the percentage of participants with laboratory-confirmed influenza associated with influenza-like illness at least 14 days after vaccination with the modRNA vaccine, as compared with the control vaccine, and analyzed for noninferiority and superiority. Immunogenicity was evaluated by means of a hemagglutination inhibition (HAI) assay. We assessed reactogenicity within 7 days after vaccination, adverse events through 1 month, and serious adverse events through 6 months. We assessed vaccine efficacy, immunogenicity, and safety in the modRNA group. RESULTS: A total of 18,476 participants underwent randomization: 9225 were assigned to receive the modRNA vaccine and 9251 to receive the control vaccine. The relative efficacy of the modRNA vaccine as compared with the control vaccine against influenza-like illness was 34.5% (95% confidence interval [CI], 7.4 to 53.9) on the basis of 57 cases in the modRNA group and 87 cases in the control group, a finding that met the criteria for both noninferiority and superiority. Cases of influenza-like illness were caused by A/H3N2 and A/H1N1 strains but almost no B strains. The noninferiority of the antibody response on HAI assay was shown for influenza A strains but not for B strains. Primarily mild or moderate reactogenicity was observed in both vaccine groups but was reported more frequently in the modRNA group (overall local reactions, 70.1% vs. 43.1%; overall systemic events, 65.8% vs. 48.7%). Fever occurred in 5.6% of the participants in the modRNA group and in 1.7% of those in the control group. Adverse event profiles were similar in the two groups. CONCLUSIONS: The modRNA vaccine had statistically superior efficacy over the control vaccine, with greater immune responses to A/H3N2 and A/H1N1 strains, but was associated with more reactogenicity events. (Funded by Pfizer; C4781004 ClinicalTrials.gov number, NCT05540522.)See also in NEJM Evidence: Human clinical trial of a nucleoside-modified mRNA influenza vaccine.

来源:N Engl J Med,查看原文。版权归原作者所有。

引用

  1. Fitz-Patrick D, McVinnie DS, Jackson LA, et al. Efficacy, Immunogenicity, and Safety of Modified mRNA Influenza Vaccine. N Engl J Med. 2025. PMID: 41259756. doi:10.1056/NEJMoa2416779

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。